Pfizer invests $43 billion to battle cancer
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spray receives FDA approval
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
US FDA Advisory Committee votes to support effectiveness and safety of GSK's respiratory syncytial virus older adult vaccine candidate
- Details
- Category: GlaxoSmithKline
![GlaxoSmithKline GlaxoSmithKline](/images/logo/gsk.png)
Pfizer receives positive FDA Advisory Committee votes supporting potential approval for vaccine candidate to help combat RSV in older adults
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate
- Details
- Category: AstraZeneca
![AstraZeneca AstraZeneca](/images/logo/astrazeneca.png)
Pfizer's elranatamab receives FDA and EMA filing acceptance
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Pfizer announces The Lancet Neurology has published Phase 3 data for zavegepant for the acute treatment of migraine in adults
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
More Pharma News ...
- Roche announces donation of essential medicines and diagnostic solutions to the people affected by the devastating earthquake in Türkiye and Syria
- Kerendia™ (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes
- GSK announces results from 17-year retrospective study on US clinical trial diversity
- 2022 Otto Bayer Award goes to Professor Frank Glorius
- Pfizer reports record full-year 2022 results
- AMJEVITA™ (adalimumab-atto), first biosimilar to Humira® now available in the United States
- CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer